


Supp Fig 1



Supplementary Figure 1. Sixteen weeks after surgery, serum was collected from a subset of mice (n=2-3/treatment group) in order to test for bioavailability of antibody using two assays on an Octet platform. **A)** Assay 1 - Free drug assessment: Streptavidin-coated sensors were loaded with 5 $\mu\text{g}/\text{mL}$ biotinylated ADAMTS-5 protein, sera was applied (diluted 1:100), followed by a challenge with goat anti-mouse IgG H+L antibody (10 $\mu\text{g}/\text{mL}$). **B)** Assay 2 - Immunogenicity/neutralization: Streptavidin-coated sensors were loaded with 10 $\mu\text{g}/\text{mL}$ biotinylated ADAMTS5 mAb (12F4.1H7), sera was applied (diluted 1:100), followed by a challenge with purified human ADAMTS5 (5 $\mu\text{g}/\text{mL}$) and a subsequent challenge with goat anti-mouse IgG H+L antibody (10 $\mu\text{g}/\text{mL}$). Real-time binding is calculated as relative intensity units (nm shift) using ForteBio Data Analysis Software v8.0.